Faculty and Agenda The full list of faculty and 2-day agenda are provided below.

Transcription

1 2018 BMT Pharmacists Conference Held in Conjunction with the 2018 BMT Tandem Meetings February 21 - February 25, 2018 Salt Palace Convention Center Salt Lake City, UT For more information about the 2018 BMT Pharmacists Conference, visit or No brochures will be mailed this year. Pharmacist Continuing Education Information Syntaxx Communications, Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Syntaxx Communications has assigned contact hours (1.325 CEUs) of continuing pharmacy education credit for this knowledge- and application-based activity. This 2-day conference will incorporate 14 individual activity sessions that combined will fulfill the hours of CE. The target audience for this accredited activity is pharmacists. To receive continuing pharmacy education credit for the conference, participants must attend the sessions in their entirety and complete the associated program evaluation forms. Additionally, all US-based pharmacists must supply their National Association of Boards of Pharmacy (NABP) electronic Profile Identification (epid) number and their birth month and day (MM/DD). No credit can or will be issued without this information. To acquire an NABP epid, go to and click on CPE Monitor. Faculty and Agenda The full list of faculty and 2-day agenda are provided below. Published February 23, 2018 February 24, 2021 Universal Activity Numbers L01-P L01-P This 2-day conference will be comprised of 14 individual sessions identified by 14 distinct UAN numbers. Overall Conference Educational Objectives After attending the 2018 BMT Pharmacists Conference, participants should be able to: 1. Summarize past and ongoing initiatives of the American Society of Blood and Marrow Transplantation (ASBMT) Pharmacy Special Interest Group. 2. Explain recent data regarding the management of hematologic malignancies and hematopoietic cell transplantation (HCT) presented at the American Society of Hematology meeting. 3. Analyze available options for the treatment of invasive fungal infection in HCT population. 4. Outline a treatment plan for a patients undergoing a HCT with Down Syndrome.

2 5. Examine the results of clinical trials supporting recently approved drugs, as well as ongoing research for emerging drugs, with indications pertinent to patients undergoing HCT. 6. Identify approaches to establishing a successful survivorship clinic to help manage the long-term complications of HCT, especially metabolic syndromes. 7. Explain the treatment opportunities and barriers in the pharmacist-led management of medicinal marijuana and opioid prescriptive practice in patients who received a HCT. 8. Assess the data for initiating maintanence therapy in patients who have undergone HCT. 9. Choose the appropriate infection prophylaxis strategy for a patients undergoing a HCT. 10. Describe the biology and recent advances in the management of chronic graft-versus-host disease following allogeneic HCT. 11. Examine the benefits of different formal approaches to the management of CRS complications associated with cellular therapy in various institutions. 12. Describe the treatment plan and monitoring parameters for a patient receiving defibrotide. 13. Identify the advancing role of the pharmacist in HCT patient management, healthcare changes in the new political landscape, issues relevant to our daily practices, and tools needed to become a patient advocate. Program Evaluation Forms The program evaluation forms may be accessed and completed online. These forms can be accessed during the conference via laptops available at various kiosks or using personal computers via a link provided on the CIBMTR and/or ASBMT Web sites ( or To access the Session Evaluation links, you will need your registration badge number; your registration badge number is provided on your name badge. Once logged on, choose the type of credit you wish to receive (ACPE), select the program you wish to evaluate, and complete the forms accordingly. When you are done, click Submit. The program will be redirected to the main menu, where you may select additional programs for evaluation. All participants completing program evaluation forms should be able to print a statement of continuing education. For problems or issues related to continuing pharmacy education, please contact Julie Marino at Syntaxx Communications: jmarino@syntaxxcomm.com Phone: or ,6416 Mail: 305 W Country Dr, Johns Creek, GA *Fees No additional fee for the 2-day (February 23, 2018 February 24, 2018) BMT Pharmacists Conference will be charged to attendees requesting continuing pharmacy education (CPE) credit. Registration for the BMT Tandem Meetings (February 21, 2018 February 25, 2018) covers attendance and CPE for any/all CPE activities. Registration Type By 10/3/17 After 10/3/17 After 1/25/18 (onsite) Member (ASBMT & CIBMTR) $650 $750 $950 Member (ASBMT or CIBMTR Only) $750 $850 $1,050 Non-Member $950 $1,050 $1,300 Allied Health Professionals $430 $570 $670 Fellows In-Training $399 $425 $480

3 *See attached Registration Fee Schedule for the 2018 BMT Tandem Meetings for full fee disclosure. Required Computer Hardware/Software Educational materials and handouts will be posted on the ASBMT and CIBMTR Web sites and available for registrants to print before the activities of this 2-day conference commence. Registrants are encouraged to print the materials before arriving at the conference. Printers will not be available onsite for conference attendee use. A business center will be available to those willing to pay for copies. Registrants will need an Internet connection in order to use the mobile application for the ARS/live polling portions of the program or the Web site (using electronic devices, such as a PC, Mac, tablet, or smart phone). Please note that PC and Apple computers do not support the Bravura Technologies Mobile Application that will be used for the ARS/live polling portion of each activity. The application to search and download for an IOS/Android tablet/mobile phone is BMTTANDEM (Bravura Technologies). Financial Support Jazz Pharmaceuticals, Incyte Corporation, Celgene Corporation Financial Disclosures (All presentations will be fully vetted by an objective, clinical peer group and Syntaxx Communications, the ACPE accredited, CPE provider) Katie Gatwood, : Jazz Pharmaceuticals: Honoraria, Advisory Board (this presentation will be carefully vetted to make sure there is no bias). Samuel Aitken, : Advisory Board and Research Support; Melinta Therapeutics/Cempra: Advisory Board; The Medicines Company: Advisory Board; Accelerate Diagnostics: Consultancy; Achaogen: Advisory Board; Zavante: Advisory Board; Merck: Other: Speaker's bureau, Advisory Board Melissa Johnson, : Charles River Laboratories: Principal Investigator, Research Funding; UpToDate, LLC: Author, Royalty; Merck & Co: Principal Investigator, Research Funding (Both sources of research funding goes to her institution) Paul Martin, MD: Neovii (Fresenius): Clinical Investigator, Research Funding; Pfizer: DSMB Member, Consultancy; Procter and Gamble: Stock, Ownership Interest (None of these financial arrangements is related to his discussion of treatment for acute GVHD. ) Craig Freyer, : Astellas Pharma: Speaker Bureau, Honoraria (This commercial interest does not relate to the content of this presentation. He receives speaking honoraria for presentations on invasive fungal infections, which is not relevant to this presentation.) John M. McCarty, MD: [Dr. McCarty is a collaborator on a Best Abstracts presention (Kathryn Maples, PhamdD)] Speakers Bureau, Principle Investigator, Honoraria and Research Funding: Celgene (Celgene manufactures azacitidine).

4 BMT Pharmacists Conference Agenda DAY 1 - Friday, February 23, 2018 Session Start / End Time Session Title Faculty 8:15 am - 8:30 am Welcome and Overview Colleen Timlin, 8:30 am - 9:45 am ASH Update Elizabeth DiMaggio, 9:45 am - 10:15 am Challenging Cases HCT in Down Syndrome Jamie Rouch, 10:15 am - 10:30 am Morning break 10:30 am - 11:00 am BMT Pharmacists SIG Update LeAnne Kennedy, 11:00 am - 12:00 pm Survivorship Metabolic Syndrome K. Scott Baker, MD 12:00 pm - 1:15 pm Lunch Break 1:15 pm - 2:15 pm New and Emerging Drugs Arpita Gandhi, 2:15 pm - 2:30 pm Afternoon break 2:30pm 3:30 pm Invasive Fungal Infections Samuel Aitken, 3:30 pm 4:30 pm Maintenance Therapy Strategies Post- Transplant Kelly Hawks, 4:30 pm 5:45 pm Best Pharmacy Abstracts A-Outcomes of a Novel Rituximab- Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemiac 10658: 8B-Maintenance Azacitidine after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies 11305: 8C-A Survey of Outpatient Medication Adherence in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients 11575: 8D-Amlodipine and Calcineurin Inhibitor Induced Nephrotoxicity Following Allogeneic Hematopoietic Stem Cell Transplant Katie S. Gatwood, Kathryn T. Maples, Lauren Ice, Ryan R Jensen,

5 DAY 2 - Saturday, February 24, 2018 Session Start / End Time Session Title Faculty 8:15 am - 8:30 am Welcome and Overview Terri Lynn Shigle, 8:30 am - 9:30 am Pharmacy Advocacy Rebecca Tombleson, ; Justin.Arnall, 9:30 am - 10:00 am Challenging Cases - Defibrotide for Management of Katie Gatwood, PhardD Veno-Occlusive Disease 10:00 am - 10:15 am Morning break 10:15 am- 11:15 am Infection Prophylaxis in HCT Patients Melissa Johnson, 11:15 am - 12:00 pm Award Presentations 12:00 pm - 1:15 pm Lunch Break 1:15 pm - 2:15 pm Cannabinoid Consult Service: Amy Carver, Fostering Safe Use of Medicinal Marijuana in the Hospital Setting 2:15 pm - 2:30 pm Afternoon break 2:30 pm - 3:30 pm Biology of cgvhd Paul Martin, MD 3:30 pm - 4:45 pm Best Practices: An Update on CAR T Cells and CRS Management with Cellular Therapy Wendy Covert,; Christina Bachmeier, ; Craig Freyer,